Shares of Pacira Pharmaceuticals (PCRX) tumbled 5.46% in after-hours trading on Tuesday following the release of its second-quarter 2025 financial results. The company reported mixed results, beating earnings estimates but falling short on revenue expectations.

Pacira BioSciences posted adjusted earnings per share (EPS) of $0.74, surpassing the analyst consensus estimate of $0.71. However, the company's quarterly revenue of $181.1 million missed the mark, coming in below the expected $183 million. This represents a modest 1.73% increase compared to the same period last year but falls short of market expectations.

The after-hours sell-off appears to be driven by multiple factors. Despite the earnings beat, the revenue miss likely disappointed investors. Additionally, Pacira narrowed its full-year 2025 total revenue guidance to a range of $730 million to $750 million, down from the previous range of $725 million to $765 million. This adjustment could be interpreted as a sign of potential challenges in the company's growth trajectory. Furthermore, the company reported a net loss of $4.8 million for the quarter, which may have contributed to negative sentiment among investors. While Pacira's adjusted EBITDA of $54.3 million exceeded estimates, it marked a decrease from the $62.1 million reported in the same quarter of the previous year, potentially raising concerns about the company's profitability trends.